Pacific Pharma, Inc.
24 drugs in NADAC|24 Generic,0 Brand
Pacific Pharma, Inc. lists 24 NDCs in the CMS NADAC file (24 generic, 0 brand), at an average NADAC of $5.50 per unit, with a week-over-week move of -1.2% across products that moved. The firm's full portfolio, pricing trend are listed below.
Total Drugs
24
24G / 0B
Avg Price / Unit
$5.5040
$0.12 – $12.67
Avg 7d Change
-1.23%
Across 20 drugs with changes
7d Activity
of 24 total drugs
Portfolio Price Trend
Monthly average NADAC price across all drugs
Keep following this manufacturer
These next-step links connect the manufacturer page to the markets, classes, and trend views most likely to deepen research.
Lead market
brimonidine tartrate market
See the molecule this manufacturer shows up in most often and compare it against competing suppliers.
Lead class
alpha-Adrenergic Agonist therapeutic class
Review the broader class where Pacific Pharma, Inc. has the strongest current portfolio footprint.
Trend hub
Portfolio trend view
Jump to the trend hub to compare this manufacturer against the rest of the market on weekly price movement.
Guide
NADAC pricing primer
Use the explainer for context on the benchmark this manufacturer is being compared against.
Frequently Asked Questions
How many drugs does Pacific Pharma, Inc. make?
Pacific Pharma, Inc. lists 24 NDCs in the CMS NADAC file — 24 generic and 0 brand products.
What is the average price of Pacific Pharma, Inc. drugs?
The average NADAC across Pacific Pharma, Inc.'s portfolio is $5.5040 per unit, ranging from $0.1241 to $12.6737.
What types of drugs does Pacific Pharma, Inc. make?
Pacific Pharma, Inc. makes drugs across 9 FDA pharmacologic classes. The most common by NDC count are alpha-Adrenergic Agonist (9), beta-Adrenergic Blocker (7), Corticosteroid (5), Sulfone (2), Cyclooxygenase Inhibitor (1).
Has Pacific Pharma, Inc. had any drug recalls?
No FDA enforcement recalls are matched to Pacific Pharma, Inc. in the openFDA feed.
How has Pacific Pharma, Inc.'s pricing changed recently?
Over the past 7 days, 7 Pacific Pharma, Inc. products rose and 13 fell, with a portfolio-wide average change of -1.2%.